Trials / Withdrawn
WithdrawnNCT03972111
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
A Phase 4, Observational Field Study to Evaluate the Safety and Clinical Benefit of TPOXX (Tecovirimat)-Treated Patients Following Exposure to Variola Virus and Clinical Diagnosis of Smallpox Disease
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- SIGA Technologies · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Phase 4, Observational Field Study in Patients Treated With TPOXX for Smallpox Disease
Detailed description
Phase 4, Observational Field Study to evaluate safety and clinical benefit of TPOXX (tecovirimat) in patients treated with TPOXX following exposure to variola virus and a clinical diagnosis of smallpox disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TPOXX 200Mg Capsule | TPOXX 600 mg (three 200 mg.) capsules twice daily for 14 days |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2024-09-30
- Completion
- 2024-09-30
- First posted
- 2019-06-03
- Last updated
- 2022-10-03
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03972111. Inclusion in this directory is not an endorsement.